Nwam LLC Has $905,000 Stake in Stryker Co. (NYSE:SYK)

Nwam LLC trimmed its holdings in Stryker Co. (NYSE:SYK) by 13.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,514 shares of the medical technology company’s stock after selling 381 shares during the period. Nwam LLC’s holdings in Stryker were worth $905,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NewEdge Wealth LLC raised its position in Stryker by 10.5% during the fourth quarter. NewEdge Wealth LLC now owns 6,250 shares of the medical technology company’s stock valued at $2,250,000 after purchasing an additional 595 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in Stryker during the fourth quarter valued at approximately $169,000. Checchi Capital Advisers LLC raised its position in Stryker by 1.4% during the fourth quarter. Checchi Capital Advisers LLC now owns 4,024 shares of the medical technology company’s stock valued at $1,449,000 after purchasing an additional 56 shares in the last quarter. Bryn Mawr Capital Management LLC raised its position in Stryker by 0.4% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 9,970 shares of the medical technology company’s stock valued at $3,590,000 after purchasing an additional 39 shares in the last quarter. Finally, Shayne & Jacobs LLC acquired a new position in Stryker during the fourth quarter valued at approximately $211,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. The Goldman Sachs Group boosted their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Argus set a $450.00 target price on shares of Stryker in a research note on Monday, February 3rd. Finally, StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Stock Performance

Shares of Stryker stock opened at $386.55 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The stock has a market cap of $147.50 billion, a price-to-earnings ratio of 49.81, a P/E/G ratio of 2.93 and a beta of 0.96. The company’s fifty day moving average is $380.50 and its 200 day moving average is $370.92.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.